New Technology– category –
-
Nanomedicine Conquers Glioblastoma’s Blood-Brain Barrier: Revolutionizing Treatment via Targeted Delivery, Stimuli-Responsiveness, and AI
Drug Target Review UK Overview Nanomedicine is emerging as a critical solution to overcome the formidable blood-brain barrier (BBB) in treating glioblastoma (GBM), the most aggressive brain tumor. Researchers are developing advanced nano... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
FDA Designates Washington University’s WU-CART-007 as Breakthrough Therapy for T-Cell Malignancies: Allogeneic Anti-CD7 CAR T-Cell Therapy Achieves 73% Complete Remission
Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine USA Overview The FDA has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by Washington University Schoo... -
ADCs Take Center Stage at HerHealth2026: A Promising Strategy for Refractory Breast and Gynecological Cancers
HerHealth2026 USA Overview At the recent HerHealth2026 conference, Antibody-Drug Conjugates (ADCs) emerged as a pivotal topic, underscoring their growing importance in treating breast and gynecological cancers. These innovative therapies... -
BioRay Pharmaceutical Advances Novel Dual-Payload TROP2 ADC, BR113, into First-in-Human Clinical Trials
AllSci China Overview China's BioRay Pharmaceutical has initiated a first-in-human Phase I trial for BR113, an innovative dual-payload TROP2 antibody-drug conjugate (ADC) targeting patients with advanced solid tumors. BR113 distinguishes... -
Nanoparticle Breakthroughs: Piercing the Blood-Brain Barrier to Revolutionize CNS Disease Treatment, Including Glioblastoma
MDPI Switzerland Overview Nanoparticle-based drug delivery systems are emerging as a pivotal solution for overcoming the blood-brain barrier (BBB), a critical challenge in treating central nervous system (CNS) diseases. A recent review h... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
Recursion Pharmaceuticals Reports Q2 Revenue Pressure but Advances First AI-Designed Neuroscience Target with Genentech to Early Discovery
Simply Wall St USA Overview Recursion Pharmaceuticals (RXRX) reported Q2 2026 revenue pressures and ongoing losses but highlighted a significant milestone: its first neuroscience target, identified through its AI drug discovery platform ... -
Generate Biomedicines Advances Novel AI-Designed Candidate GB-4362 to Clinical Development, Pushing Tolerability Limits
Generate:Biomedicines (Blog Posts) USA Overview Generate:Biomedicines announced the advancement of its novel candidate drug, GB-4362, designed using its generative biology platform, into clinical development. This milestone exemplifies t... -
Merck Achieves Robust Q2 2026 Performance, Upgrades Full-Year Guidance, and Empatran Secures FDA Breakthrough Therapy Designation for Lupus
Merck USA Overview Merck reported strong second-quarter 2026 financial results and consequently upgraded its full-year guidance, bolstered by the U.S. FDA's Breakthrough Therapy Designation for Empatran in July. Empatran, developed for l...
